With this and the broker report DXB is getting all its ducks in a row prior to the release of the detailed Phase 2 results next week.
Certainly doing its best to avoid a post-consolidation price drop!
Ann: Ethics Committee Approval for Pharmacokinetic Trial, page-2
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
-0.015(3.30%) |
Mkt cap ! $242.0M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 47.5¢ | 43.0¢ | $1.696M | 3.836M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 69541 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 26902 | 2 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |